Global Point of Care & Rapid Diagnostics Market to Grow by 12.45% Annually Through 2029 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Point of Care & Rapid Diagnostics Market Analysis by Product, by Platform, by Mode of Purchase, End user and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The point of care & rapid diagnostics market size is estimated to be USD 38.7 billion in 2021 and is expected to witness a CAGR of 12.45% during the forecast period 2022-2029. The increasing frequency of infectious disease, supporting government policies, and the rising number of CLIA-waived POC tests are some of the key drivers for the market growth. Furthermore, healthcare decentralisation and increased investments and funding for product development are expected to contribute the market growth. However, reimbursement reduction and budget restrictions are expected to restrain the market growth.

Segmentation: Point of Care & Rapid Diagnostics Market Report 2021-2029

Product (Revenue, USD Billion)

• Cardiometabolic Monitoring Products
• Glucose Monitoring Products
• Coagulation Monitoring Products
• Infectious Disease Testing Products
• Cholesterol Testing Products
• Faecal Occult Testing Products
• Haematology Testing Products
• Urinalysis Testing Products
• Others

By Platform (Revenue, USD Billion)

• Molecular Diagnostics
• Lateral Flow Assays
• Immunoassays
• Microfluids
• Dipsticks

By Mode of Purchase (Revenue, USD Billion)

• OTC Products
• Prescription-based Products

By End user (Revenue, USD Billion)

• Ambulatory Care Facilities & Physician Offices
• Hospitals
• Clinical Laboratories
• Pharmacies
• Home Care & Self Testing
• Others

By Region (Revenue, USD Billion)

North America

• U.S
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• GCC
• Rest of MEA

Key Topics Covered:

1. Research Methodology

2. Introduction: Point of Care & Rapid Diagnostics

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Point of Care & Rapid Diagnostics Market

7. Market Analysis by Product

8. Market Analysis by Platform

9. Market Analysis by Mode of Purchase

10. Market Analysis by End user

11. Regional Market Analysis

12. North America Point of Care & Rapid Diagnostics Market

11. Europe Point of Care & Rapid Diagnostics Market

12. Asia PacificPoint of Care & Rapid Diagnostics Market

13. Latin America Point of Care & Rapid Diagnostics Market

14. MEAPoint of Care & Rapid Diagnostics Market

15. Competitor Analysis

16. Company Profiles

17. Conclusion & Recommendations

Companies Mentioned

• Abbott Laboratories (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• bioMerieux SA (France)
• Danaher Corporation (US)
• Quidel Corporation (US)
• QIAGEN N.V. (Netherlands)
• Co-Diagnostics Inc. (US)
• Biocartis NV (Belgium)
• Meridian Bioscience Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Lucira Health Inc. (US)
• Cue Health (US)
• OpGen Inc. (US)
• Binx Health Inc. (US)
• Molbio Diagnostics Pct. Ltd. (India)
• Genomadix (Canada)
• Visby Medical Inc. (US)
• QuikPath PTE Ltd. (Singapore)
• MD-Bio (US)
• QuantuMDx Group Ltd. (UK)
• Aidian Oy (Finland)
• GeneSTAT Molecular Diagnostics LLC (US).

For more information about this report visit https://www.researchandmarkets.com/r/7rynpb